← Evidence map

ArticleCancers2025

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Viktor Grünwald et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex. | OpenQuestion